论文部分内容阅读
目的探讨艾迪注射液辅助奈达铂局部化疗对恶性胸腔积液治疗的临床疗效。方法采用抽签法将收治的67例恶性胸腔积液患者分为A组(33例)和B组(34例),A组采用顺铂治疗,B组采用艾迪注射液辅助奈达铂治疗,治疗4周后,应用酶联免疫吸附试验(ELISA)方法对两组患者治疗前后胸腔积液癌胚抗原(CEA)水平进行检测,观察两组患者临床疗效和不良反应。结果两组患者近期疗效和生活质量比较,B组显著高于A组(P<0.05);B组患者经4周治疗后胸腔积液CEA水平降低程度明显大于A组(P<0.05);B组患者不良反应明显低于A组(P<0.05)。结论艾迪注射液辅助奈达铂局部化疗可显著提高恶性胸腔积液治疗疗效,减轻化疗不良反应,提高患者生存质量。
Objective To investigate the clinical efficacy of Aidi injection in adjuvant nedaplatin topical chemotherapy in the treatment of malignant pleural effusion. Methods Sixty-seven patients with malignant pleural effusion were divided into group A (n = 33) and group B (n = 34) by random selection. Group A received cisplatin and group A received aid injection of nedaplatin. After 4 weeks of treatment, the levels of carcinoembryonic antigen (CEA) in pleural effusion before and after treatment were detected by enzyme linked immunosorbent assay (ELISA), and the clinical efficacy and adverse reactions in both groups were observed. Results The curative effect and quality of life in the two groups were significantly higher than those in group A (P <0.05). The level of CEA in group B was significantly higher than that in group A (P <0.05) after 4 weeks of treatment. Adverse reactions were significantly lower in group A than in group A (P <0.05). Conclusion Aidi injection assisted with local nedaplatin chemotherapy can significantly improve the efficacy of malignant pleural effusion, reduce chemotherapy adverse reactions and improve patient quality of life.